Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease
European Journal of Nuclear Medicine and Molecular Imaging · 2023-12 · 51 (1) · 136-146
DOI: 10.1007/s00259-023-06455-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 09.10.2023. Verfasst von Alexis Poitrasson-Rivière und 10 weiteren Autor:innen. Beteiligte Einrichtung: INVIA Medical Imaging Solutions, 3025 Boardwalk Dr., Suite 200, Ann Arbor, MI, 48108, USA. apoitrasson@inviasolutions.com. Hauptthemen laut MEDLINE: Atherosclerosis, Coronary Artery Disease, Fractional Flow Reserve, Myocardial, Myocardial Perfusion Imaging. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
PURPOSE: Distinguishing obstructive epicardial coronary artery disease (CAD) from microvascular dysfunction and diffuse atherosclerosis would be of immense benefit clinically. However, quantitative measures of absolute myocardial blood flow (MBF) integrate the effects of focal epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. In this study, MFR and relative perfusion quantification were combined to create integrated MFR (iMFR) which was evaluated using data from a large clinical registry and an international multi-center trial and validated against invasive coronary angiography (ICA). METHODS: This study included 1,044 clinical patients referred for 82Rb rest/stress positron emission tomography myocardial perfusion imaging and ICA, along with 231 patients from the Flurpiridaz 301 trial (clinicaltrials.gov NCT01347710). MFR and relative perfusion quantification were combined to create an iMFR map. The incremental value of iMFR was evaluated for diagnosis of obstructive stenosis, adjusted for patient demographics and pre-test probability of CAD. Models for high-risk anatomy (left main or three-vessel disease) were also constructed. RESULTS: iMFR parameters of focally impaired perfusion resulted in best fitting diagnostic models. Receiver-operating characteristic analysis showed a slight improvement compared to standard quantitative perfusion approaches (AUC 0.824 vs. 0.809). Focally impaired perfusion was also associated with high-risk CAD anatomy (OR 1.40 for extent, and OR 2.40 for decreasing mean MFR). Diffusely impaired perfusion was associated with lower likelihood of obstructive CAD, and, in the absence of transient ischemic dilation (TID), with lower likelihood of high-risk CAD anatomy. CONCLUSIONS: Focally impaired perfusion extent derived from iMFR assessment is a powerful incremental predictor of obstructive CAD while diffusely impaired perfusion extent can help rule out obstructive and high-risk CAD in the absence of TID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INVIA Medical Imaging Solutions, 3025 Boardwalk Dr., Suite 200, Ann Arbor, MI, 48108, USA. apoitrasson@inviasolutions.com.
- INVIA Medical Imaging Solutions, 3025 Boardwalk Dr., Suite 200, Ann Arbor, MI, 48108, USA.
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
- GE Pharmaceutical Diagnostics R&D, Amersham, UK.
- Houston Methodist Debakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, USA.
- Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
ORCID-Profile: Alexis Poitrasson-Rivière
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Poitrasson-Rivière, A., Moody, J. B., Renaud, J. M., Hagio, T., Arida-Moody, L., Buckley, C. J., Al-Mallah, M. H., Nallamothu, B. K., Weinberg, R. L., Ficaro, E. P., & Murthy, V. L. (2023). Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging, 51(1), 136-146. https://doi.org/10.1007/s00259-023-06455-2
Vancouver
Poitrasson-Rivière A, Moody JB, Renaud JM, Hagio T, Arida-Moody L, Buckley CJ, et al. Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging. 2023;51(1):136-146. doi:10.1007/s00259-023-06455-2
BibTeX
@article{PoitrassonRivire2023,
author = {Poitrasson-Rivière, Alexis and Moody, Jonathan B and Renaud, Jennifer M and Hagio, Tomoe and Arida-Moody, Liliana and Buckley, Christopher J and Al-Mallah, Mouaz H and Nallamothu, Brahmajee K and Weinberg, Richard L and Ficaro, Edward P and Murthy, Venkatesh L},
title = {Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {51},
number = {1},
pages = {136--146},
doi = {10.1007/s00259-023-06455-2}
}
EUVIMED